Each article is made available under the terms of the Creative Commons Attribution Non-Commercial License. ​All of our articles are available to download individually in PDF format.


Cardiovascular Risk Factor Control in Type 2 Diabetes Mellitus and New Trial Evidence

Cardiovascular Risk Factor Control in Type 2 Diabetes Mellitus and New Trial Evidence

March 2, 2017 at 8:20 AM 0 comments

*Peter M. Nilsson Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden *Correspondence to Peter.Nilsson@med.lu.se Disclosure: The author has declared no conflicts of interest. Acknowledgements: The review was supported by a grant from the Research Council and the Heart and Lung Foundation of Sweden. Received: 19.09.16 Accepted: 28.11.16Read More

Sedentary Behaviour: A New Target in the Prevention and Management of Diabetes?

Sedentary Behaviour: A New Target in the Prevention and Management of Diabetes?

December 13, 2016 at 8:29 AM 0 comments

*Julianne D. van der Berg,1,2,3 Annemarie Koster,1,2 Coen D.A. Stehouwer4,5 1. Department of Social Medicine, Maastricht University, Maastricht, Netherlands 2. CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, Netherlands 3. Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands 4. Department of Internal Medicine, MaastrichtRead More

Management of Cardiovascular Risk Factors in Type 2 Diabetes Mellitus Patients

Management of Cardiovascular Risk Factors in Type 2 Diabetes Mellitus Patients

December 13, 2016 at 8:20 AM 0 comments

Iciar Martín-Timón, Cristina Sevillano-Collantes, Juan José Marín-Peñalver, *Francisco Javier del Cañizo-Gómez Endocrinology Department, University Hospital Infanta Leonor, School of Medicine, Complutense University, Madrid, Spain *Correspondence to fjcanizog@salud.madrid.org Disclosure: The authors have declared no conflicts of interest. Received: 07.06.16 Accepted: 29.09.16 Citation: EMJ. 2016;1[4]:89-97. Abstract People with Type 2 diabetes mellitusRead More

Type 2 Diabetes Mellitus: Beyond the Beta Cell

Type 2 Diabetes Mellitus: Beyond the Beta Cell

October 27, 2016 at 8:29 AM 0 comments

This symposium took place on 12th September 2016 as a part of the European Association for the Study of Diabetes (EASD) Annual Meeting in Munich, Germany Chairpersons: Baptist Gallwitz,1 Jiten Vora2 Speakers: Chantal Mathieu,3 Juris Meier,4 Jens Holst,5 Marcus Schindler6 1. Department of Medicine IV, Tübingen University Hospital, Tübingen, Germany 2. Royal LiverpoolRead More

Editor’s Pick: New Drugs for Type 2 Diabetes: New Hopes and New Concerns About the Skeleton

Editor’s Pick: New Drugs for Type 2 Diabetes: New Hopes and New Concerns About the Skeleton

October 27, 2016 at 8:28 AM 0 comments

Dr Berberoglu’s paper is a highly pertinent look at a new complication of diabetes: skeletal fragility. The skeletal effects of a variety of newly approved drugs used in the treatment of Type 2 diabetes mellitus are discussed, indicating the need for future research to specifically identify patients who are mostRead More

Treatment of Type 2 Diabetes with Biphasic Insulin Analogues

Treatment of Type 2 Diabetes with Biphasic Insulin Analogues

October 27, 2016 at 8:27 AM 0 comments

*Ali A. Rizvi Professor of Medicine, Department of Medicine and Director, Division of Endocrinology, University of South Carolina School of Medicine, Columbia, South Carolina, USA *Correspondence to Ali.Rizvi@uscmed.sc.edu Disclosure: The author has received grant support, as principal investigator at the University of South Carolina site, from the National Institutes of Health (NIH)Read More

Utility of Glycated Haemoglobin in Gestational Diabetes Mellitus: Present and Future

Utility of Glycated Haemoglobin in Gestational Diabetes Mellitus: Present and Future

October 27, 2016 at 8:26 AM 0 comments

*Rajesh Rajput,1 Deepak Jain2 1. Department of Endocrinology and Medicine VI, Pt. B D Sharma Postgraduate Institute of Medical Sciences, Rohtak, Haryana, India 2. Department of Medicine, Sharma University of Health Sciences, Rohtak, Haryana, India *Correspondence to drrajeshrajput@outlook.com Disclosure: The authors have declared no conflicts of interest. Received: 21.06.16 Accepted: 04.10.16Read More

Treatment Strategies for Chorioretinal Vascular Diseases: Advantages and Disadvantages of Individualised Therapy

Treatment Strategies for Chorioretinal Vascular Diseases: Advantages and Disadvantages of Individualised Therapy

October 27, 2016 at 8:25 AM 0 comments

*Michael W. Stewart Professor and Chairman, Mayo School of Medicine, Department of Ophthalmology, Mayo Clinic, Jacksonville, Florida, USA *Correspondence to stewart.michael@mayo.edu Disclosure: The author acknowledges the following relationships: Allergan: Institutional research support, Advisory Board; Boehringer-Ingelheim: Consultant; Momenta Pharmaceuticals: Consultant and Regeneron; Institutional research support, Advisory Board. However, no external funding or assistance wasRead More

Anti-Hyperglycaemic and Lipid Profile Regulatory Properties of Moringa Oleifera in Subjects at Early Stages of Type 2 Diabetes Mellitus

Anti-Hyperglycaemic and Lipid Profile Regulatory Properties of Moringa Oleifera in Subjects at Early Stages of Type 2 Diabetes Mellitus

October 27, 2016 at 8:24 AM 0 comments

*Bienvenu Tollo,1,2 Daniel C. Chougourou,2 Clovis Maurès Todohoue1 1. African Diabetes Management Institute, Cotonou, Republic of Benin 2. Research Laboratory of Applied Biology, University of Abomey-Calavi, Abomey-Calavi, Republic of Benin *Correspondence to bientollo@yahoo.de Disclosure: We acknowledge support from the Research Laboratory of Applied Biology, University of Abomey-Calavi, the Clinical Trial Research UnitRead More

Treating the Diabetic Hypertensive: Consensus and Differences

Treating the Diabetic Hypertensive: Consensus and Differences

July 5, 2016 at 8:21 AM 0 comments

*Abdul Rashid Rahman An Nur Specialist Hospital, Bandar Baru Bangi, Selangor, Malaysia *Correspondence to abdulrashid43000@gmail.com Disclosure: The author has declared no conflicts of interest. Received: 29.02.16 Accepted: 31.05.16 Citation: EMJ Nephrol. 2016;4[1]:98-104. Abstract Hypertension and diabetes commonly coexist. Both are major modifiable risk factors for cardiovascular diseases. There has beenRead More